Wednesday, November 25, 2009, 2:46pm EST - Canadian Markets close in 1 hour and 14 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Rigel Pharmaceuticals, Inc. (RIGL)

At 14:30 EST: 8.06 USD  Up 0.06 (0.75%)  
MORE ON RIGL
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Rigel Pharmaceuticals, Inc. (NGM:RIGL) Delayed quote dataEdit
Last Trade: 8.06 USD
Trade Time: 2:30PM EST
Change: Up 0.06 (0.75%)
Prev Close: 8.00
Open: 8.03
Bid: 8.06 x 500
Ask: 8.07 x 500
1y Target Est: 15.70
Day's Range: 7.97 - 8.10
52wk Range: 4.19 - 14.75
Volume: 303,464
Avg Vol (3m): 818,665
Market Cap: 417.68M
P/E (ttm): N/A
EPS (ttm): -3.24
Div & Yield: N/A (N/A%)
Rigel Pharmaceuticals, Inc. (RIGL)
1d  5d  3m  6m  1y  2y  5y  max 
 Add RIGL to Portfolio   Download Data

HEADLINES
Rigel shares rise on RBC analyst upgrade
AP (Mon, Nov 23)
Rigel Pharms upgraded by RBC Capital Mkts
Briefing.com (Mon, Nov 23)
Piper Jaffray Award Winning Analyst Says Health Care Reform Equity Valuation Fears Have Passed: Stock Picks For Q4 2009
Wall Street Transcript (Tue, Nov 10)
Bristol Licenses Arthritis Drug: BioBuzz
at TheStreet.com (Tue, Nov 10)
Biosimilars, Biologics, Biotech And Specialty Pharmaceuticals: Piper Jaffray Picks The Stocks And Sectors With Highest Potential Returns For Investors
Wall Street Transcript (Fri, Nov 6)
RIGEL PHARMACEUTICALS INC Financials
EDGAR Online Financials (Fri, Nov 6)
New Star Analyst Rankings for Rigel Pharmaceuticals, Inc.
StarMine (Wed, Nov 4)
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
EDGAR Online (Tue, Nov 3)
Rigel reports $26.7M loss in Q3
at bizjournals.com (Tue, Nov 3)
UPDATE - Rigel to move arthritis drug forward; posts weak Q3
at Reuters (Tue, Nov 3)
More Headlines for RIGL...

ANALYST
EPS Est (next year) (Dec-09) : -2.72
EPS Est (in 2 years) (Dec-10) : -1.35
Avg Rec (current)*: 1.8
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News Canadian Indices